Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Adam Eckert

Sierra Oncology Stock Is Soaring: Here's Why

Sierra Oncology Inc (NASDAQ:SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE:GSK) for $55 per share in cash, representing an approximate total equity value of $1.9 billion. 

GSK believes Sierra Oncology's momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.